北美缺铁性贫血治疗市场 – 行业趋势和 2030 年预测

北美缺铁性贫血治疗市场分析及规模

贫血是当今最常见的血液疾病之一。静脉注射铁剂药物正面临广泛的应用，因为它们提高了透析以外的治疗质量，增加了透析患者的数量，增加了北美糖尿病患者的数量，并且人口老龄化加剧。大量研究支持在医院环境中使用口服铁剂疗法代替静脉注射治疗，预计这也将增加口服铁剂疗法在人群中的采用率。

Data Bridge Market Research 分析了 2023-2030 年预测期内缺铁性贫血治疗市场的增长率。在上述预测期内，缺铁性贫血治疗市场的预期复合年增长率约为 18.2%。2022 年市场价值为 380.6115 亿美元，到 2030 年将增长至 1450.179 亿美元。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 整理的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

北美缺铁性贫血治疗市场范围和细分

Market Definition

Iron deficiency anemia is a type of anemia that occurs when the body's iron stores are reduced. An inadequacy of healthy red blood cells specifies anemia. RBCs supply oxygen to human tissues. Iron is important in the production of haemoglobin. Haemoglobin deficiency shows lack of oxygen in the body. It's essential to keep your iron levels in check. Iron-rich foods such as meat, vegetables, fruits, and cereals can help treat or prevent iron deficiency. Vitamin C can help to prevent iron deficiency.  

North America Iron-Deficiency Anemia Therapy Market Dynamics

Drivers

• Increasing Prevalence of Chronic Kidney Disease

As per the statistics of National Kidney Foundation, Inc., the two main causes of chronic kidney disease are diabetes and hypertension. More than 1 in 7, as in approximately 15% of U.S. adults or 37 million people, are projected to have CKD. Around 434.3 million people have CKD across the varied regions of North America, with most of the disease burden witnessed in China and India (up to 299.9 million). It is anticipated that the prevalence of chronic kidney cases will rise across highly economic countries, such as the U.S., which infers an increase in the aged population over the upcoming years. 

• Growing Research and Clinical Activities

The rising number of research that supports the use of oral iron therapy as a substitute to intravenous treatments in hospital settings is anticipated to increase the adoption of oral iron therapy, thus increasing the segment growth. For instance, as per the latest study published by the IRESPUB Journal of Life Sciences, in January 2022, named "Oral iron formulae for treatment of iron deficiency anemia: a comparative study", oral iron supplementation has been considered the main solution for the treatment of iron deficiency anemia in children that impact their growth and development. Thus, this boosts the growth of the market.

Opportunities

• Increase in Anaemia

The increasing prevalence of iron deficiency anemia because of lack of sufficient iron quantities in food and excessive loss of red blood cells, particularly in women and children can lead to developmental defects in fetal problems in pregnant women and growing children, respectively. It has been observed that about 53% of the women were found to be anemic in 2020.  According to the records of the National Heart, Lung, and Blood Institute, an expected 3 million individuals suffer from anaemia in North America. Increasing occurrence of target diseases, such as autoimmune diseases, rheumatoid arthritis, kidney conditions, liver disorders, cancer, thyroid diseases, and inflammatory bowel diseases, is a primary factor helping in the growth of the market for intravenous iron. Thus, it creates opportunity for the market growth.

• Increasing Incidence of Cancer

A rising number of cancer patients tend to develop iron deficiency anemia. Common types of cancer that are widely associated with anemia includes bone cancer, cervical cancer, blood cancer, colon cancer, and prostate cancer. Lung and breast tumors have been specified with the highest prevalence of anemia among solid tumors. Hematologic malignancies such as lymphoma, leukemia, and multiple myeloma produce abnormal blood cells that as a result harm the immune system and cause anemia. Cancer treatments such as chemotherapy and radiation therapy also increase anemia in cancer patients. This creates more opportunity in the market.

Restraints/Challenges

• Serious Effects of Iron Supplements

There are few serious effects that are associated with the intake of iron drugs. Common effects include digestive problems such as loss of appetite, nausea, stomach aches, constipation, and vomiting. The overdose of these drugs may also cause tiredness or weakness, shallow or rapid breathing, fatigue, bluish skin, convulsions, pale skin or fingernails. Thus, this impedes the market growth.

This North America iron-deficiency anemia therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the North America iron-deficiency anemia therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19  Impact on North America Iron-Deficiency Anemia Therapy Market

COVID-19 疫情扰乱了静脉注射铁剂的生产和供应，但是，制造商和政府为满足需求而采取的举措不断增加，促进了静脉注射铁剂市场的增长。除此之外，许多研究表明，Covid-19 感染具有很大的急性肾损伤 (AKI) 和 CKD 风险，这反过来又刺激了对用于治疗 CKD 相关贫血的静脉注射铁剂的需求。卫生当局建议，患有急性肾损伤的 COVID-19 患者应经常接受检测，因为他们患 CKD 的风险高于其他人。因此，COVID-19 对市场增长产生了重大影响。

北美缺铁性贫血治疗市场范围

北美缺铁性贫血治疗市场根据治疗、治疗领域、人口、分销渠道和最终用户进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

治疗

• 肠外铁疗法
• 口服铁剂疗法

治疗领域

• 炎症性肠病
• 肾脏
• 妇产科
• 充血性心力衰竭 (CHF)
• 肿瘤学
• 其他的

人口

• 成年人
• 儿科
• 老年

最终用户

• 何医院​​​​​​​医院
• 专科诊所
• 家庭护理
• 其他的

分销渠道

• 医院药房
• 零售药店
• 网上药店
• 其他的

缺铁性贫血治疗市场区域分析/见解

对北美缺铁性贫血治疗市场进行了分析，并按上述治疗、治疗领域、人口、分销渠道和最终用户提供了市场规模洞察和趋势。

北美缺铁性贫血治疗市场报告涉及的主要国家 有英国、德国、法国、西班牙、意大利、荷兰、瑞士、俄罗斯、土耳其、比利时。 

德国在市场上处于领先地位，因为其医疗保健系统的质量和管理，以及科学家在贫血药物方面的研究和开发活动日益增多。此外，与缺铁性贫血治疗相关的产品审批数量不断增加，以及公司越来越重视开发有效的治疗方法，预计将在预测期内推动该地区的市场增长。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和北美缺铁性贫血治疗市场份额分析

北美缺铁性贫血治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对北美缺铁性贫血治疗市场的关注有关。

北美缺铁性贫血治疗市场的主要参与者包括：

• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 拜耳公司（德国）
• Cipla Inc.（美国）
• 雅培（美国）
• AbbVie Inc.（美国）
• 太阳制药工业有限公司 (印度)
• Aurobindo Pharma（印度）
• 鲁冰花（印度）
• Hikma Pharmaceuticals PLC（英国）
• Covis Pharma GmbH（美国）
• PHARMACOSMOS A/S（丹麦）
• Vifor Pharma Management Ltd.（瑞士）
• Orion 公司 (芬兰)
• Shield Therapeutics（英国）
• Advanz 制药 (英国)
• Alkem Labs（印度）

SKU-52743